TITLE

Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis

AUTHOR(S)
Wong, David K.H.; Cheung, Angela M.; O'Rourke, Keith; Naylor, C. David; Detsky, Allan S.; Heathcote, Jenny; Wong, D K; Cheung, A M; O'Rourke, K; Naylor, C D; Detsky, A S; Heathcote, J
PUB. DATE
August 1993
SOURCE
Annals of Internal Medicine;8/15/93, Vol. 119 Issue 4, p312
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Purpose: To determine whether alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic hepatitis B virus (HBV) infection.Data Sources: Randomized controlled studies published in the English literature between January 1966 and June 1992 were identified through a MEDLINE computer search.Study Selection: Fifteen randomized controlled studies with a total of 837 adult chronic HBV carriers who were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were identified. Studies were included if patients were treated for at least 3 months and followed for at least 6 months after cessation of therapy.Results: Overall, the loss of HBsAg occurred 6% more often in interferon-treated patients than the natural seroconversion seen in controls (7.8% compared with 1.8%, P = 0.001), and the loss of viral replication occurred approximately 20% more often in treated patients than in controls (33% compared with 12% for loss of HBeAg and 37% compared with 17% for the loss of HBV DNA, P = 0.0001) if patients received interferon for 3 to 6 months and were followed for 6 to 12 months. Interferon also had a significant treatment effect on the development of antibodies to HBsAg (anti-HBs), antibodies to HBeAg (anti-HBe), and on the normalization of alanine aminotransferase levels.Conclusions: Alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic HBV infection who are HBeAg positive when these patients are treated for 3 to 6 months and followed for 6 to 12 months after cessation of therapy. Follow-up studies are required to determine whether interferon reduces the risk for developing cirrhosis or hepatocellular carcinoma.
ACCESSION #
6995418

 

Related Articles

  • Genotype Mixtures of Hepatitis B Virus in Patients Treated with Interferon. Hannoun, Charles; Krogsgaard, Kim; Horal, Petr; Lindh, Magnus // Journal of Infectious Diseases;9/15/2002, Vol. 186 Issue 6, p752 

    Little is known about coinfection among several hepatitis B virus (HBV) genotypes, although previous reports of recombination and genotype shifts indicate that this should occur. In the present study, we designed a method to identify mixtures of genotype A and another genotype, regardless of...

  • Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Eto, Toshiharu; Takahashi, Hiroshi // Nature Medicine;May99, Vol. 5 Issue 5, p577 

    Most chronic carriers of hepatitis D virus (HDV) do not respond to interferon (IFN) treatment. This limitation of IFN therapy may be due in part to scant expression of IFN receptor in the liver. Decause the asialoglycoprotein (ASGP) receptor is specifically expressed in the liver at high...

  • Comparison of 12-Month Courses of Interferon-α -2b--Lamivudine Combination Therapy and Interferon-α -2b Monotherapy among Patients with Untreated Chronic Hepatitis B. Yalcin, Kendal; Degertekin, Halil; Yildiz, Fetin; Celik, Yusuf // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1516 

    We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lami-vudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received...

  • An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients. Ali, Liaqat; Idrees, Muhammad; Ali, Muhammad; Rehman, Irshad-ur; Hussain, Abrar; Afzal, Samia; Butt, Sadia; Saleem, Sana; Munir, Saira; Badar, Sadaf // Virology Journal;2011, Vol. 8 Issue 1, p1 

    Hepatitis B virus (HBV) is one of the leading health problem with up to 350 million affected people worldwide including 4.5 million only in Pakistan. It has mortality rate of 0.5 to 1.2 million per year worldwide. Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country. The...

  • AASLD Updates Chronic Hepatitis B Recommendations. HUNTZINGER, AMBER // American Family Physician;2/15/2009, Vol. 79 Issue 4, p338 

    The article focuses on the updated chronic hepatitis B virus (HBV) infection recommendations from the American Association for the Study of Liver Diseases (AASLD), which include the preferred diagnostic, therapeutic, and preventive approaches to chronic HBV. It notes that chronic HBV infection...

  • Infections.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p11 

    The article discusses research concerning chronic hepatitis infections including one by V. Rijckborst and colleagues and another by M. J. Sonneveld and colleagues. The first study dealt with the early-on treatment diagnosis of response to peginterferon alfa-2a for patients with HBeAg-negative...

  • Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. Someya, Takashi; Ikeda, Kenji; Saitoh, Satoshi; Kobayashi, Masahiro; Hosaka, Tetsuya; Sezaki, Hitomi; Akuta, Norio; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Arase, Yasuji; Kumada, Hiromitsu // Journal of Gastroenterology;Dec2006, Vol. 41 Issue 12, p1206 

    Hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) often recurs after surgical or medical treatment. Eighty consecutive patients with HBV-positive cirrhosis and HCC who underwent potentially curative ablation for HCC were analyzed. Eleven patients received long-term interferon...

  • Suppressing Hepatitis B without Resistance – So Far, So Good. Mailliard, Mark E.; Gollan, John L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p848 

    The article presents the authors' comments on the management of hepatitis B. The authors mention that clinicians managing patients with chronic viral hepatitis face complex challenges. They say that the prime objective of therapy for chronic hepatitis is to heal hepatic inflammation and...

  • Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Lisker-Melman, Mauricic; Webb, David; Di Bisceglie, Adrian M.; Kassianides, Chris; Martin, Paul; Rustgi, Vinod; Waggoner, Jeanne G.; Park, Yoon; Hoofnagle, Jay H.; Lisker-Melman, M; Webb, D; Di Bisceglie, A M; Kassianides, C; Martin, P; Rustgi, V; Waggoner, J G; Park, Y; Hoofnagle, J H // Annals of Internal Medicine;9/15/89, Vol. 111 Issue 6, p479 

    Study Objectives: To assess the efficacy of alpha-interferon therapy in patients with hepatitis B virus (HBV)-related glomerulonephritis.Design: Prospective, nonrandomized study.Patients: Five patients with persistence of hepatitis B surface antigen,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics